Previous 10 | Next 10 |
Piper Sandler has initiated Ironwood Pharmaceuticals (NASDAQ:IRWD) at overweight citing the success of the company's irritable bowel syndrome drug Linzess (linaclotide). The firm has a $16 price target (~36% upside based on Thursday's close). Analyst David Amsellem said that Linzess has three...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 5, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and ...
PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2021 Earnings Conference Call February 17, 2022 08:30 A.M. ET Company Participants Matt Roache - Director of IR Thomas McCourt - CEO Michael Shetzline - CMO and Head of R&D Sravan K. Emany - CFO Conference Call Participants Boris Peaker - Cowen &am...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals press release (NASDAQ:IRWD): Q4 Non-GAAP EPS of $0.27 misses by $0.07. Revenue of $117.13M (+0.4% Y/Y) beats by $6.96M. Guidance: FY22 The company expects the revenue to be between $420M -$430M (consensus of $426.90M). Adjusted EBITDA expected to be >$25...
– 2021 total revenue of $414 million, driven primarily by $400 million in U.S. LINZESS collaboration revenue – – 2021 GAAP net income of $528 million, includes a $338 million non-recurring income tax benefit related to the release of the valuation al...
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q4 earnings results on Thursday, February 17th, before market open. The consensus EPS Estimate is $0.34 (-5.6% Y/Y) and the consensus Revenue Estimate is $110.17M (-5.6% Y/Y). Over the last 2 years, IRWD has beaten EPS estimates ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 17, 2022. Individuals interested in participating in the call should dial (888...
– LINZESS Expected to Achieve Blockbuster Status with U.S. Net Sales in Excess of $1 Billion in 2021 – – Initiates Board Authorized Share Repurchase Program in Q4 2021 – – Expects Continued Double-Digit LINZESS® P...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...